This phase II trial compares the combination of selinexor, daratumumab, Velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-risk newly diagnosed multiple myeloma. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The drugs daratumumab, lenalidomide, bortezomib, dexamethasone and selinexor are already approved by the FDA for use in myeloma. But selinexor is not used until myeloma comes back (relapses) after initial treatment. Giving selinexor in the initial treatment may be a superior type of treatment for patients with high-risk newly diagnosed multiple myeloma.

开始日期2024-11-16

申办/合作机构

National Cancer Institute

NCT06348147 / Not yet recruiting临床2期IIT

An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation

This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.

开始日期2024-08-01

申办/合作机构

UNC Lineberger Comprehensive Cancer Center

NCT06287944 / Not yet recruiting临床1期IIT

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatment for donor stem cell transplant in patients with high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Radioimmunotherapy is treatment with a radioactive substance that is linked to a monoclonal antibody, such as daratumumab, that will find and attach to cancer cells. Radiation given off by the radioisotope my help kill the cancer cells. Chemotherapy drugs, such as fludarabine and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. TMLI is a targeted form of body radiation that targets marrow, lymph node chains, and the spleen. It is designed to reduce radiation-associated side effects and maximize therapy effect. Actinium Ac 225-DOTA-daratumumab combined with fludarabine, melphalan and TMLI may be safe, tolerable, and/or effective as conditioning treatment for donor stem cell transplant in patients with high-risk AML, ALL, and MDS.

开始日期2024-06-18

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与达雷妥尤单抗相关的临床结果

登录后查看更多信息

100 项与达雷妥尤单抗相关的转化医学

登录后查看更多信息

100 项与达雷妥尤单抗相关的专利（医药）

登录后查看更多信息

1,458

项与达雷妥尤单抗相关的文献（医药）

2024-03-01·American Journal of Hematology

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA

Article

作者: Malandrakis, Panagiotis ; Dimopoulos, Meletios A ; Kastritis, Efstathios ; Delimpasi, Sosana ; Manousou, Kyriaki ; Symeonidis, Argiris ; Katodritou, Eirini ; Terpos, Evangelos ; Verrou, Evgenia ; Gavriatopoulou, Maria ; Ntanasis-Stathopoulos, Ioannis ; Hatjiharissi, Evdoxia ; Golfinopoulos, Stavros ; Migkou, Magdalini

Abstract:

The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple myeloma (MM) has increased the number of those who become refractory to lenalidomide at second line. In this context, we assessed the efficacy of daratumumab in combination with ixazomib and dexamethasone (Dara‐Ixa‐dex) in the prospective phase 2 study DARIA. Eligible patients had relapsed/refractory MM (RRMM) after one prior line with a lenalidomide‐based regimen. The primary endpoint was overall response rate (ORR). Secondary endpoints included survival outcomes, safety and changes in biomarkers of bone metabolism. Overall, 50 patients were enrolled (median age 69 years, 56% males). 32 (64%) patients were refractory to lenalidomide, and 17 (34%) had undergone autologous transplant. The ORR was 64% (n = 32); whereas 17 (34%) had a very good partial response or better. The median time to first response was 1.0 month. After a median follow‐up of 23.4 months, the median PFS and OS were 8.1 and 39.2 months, respectively. Furthermore, significant changes in markers of bone metabolism became evident as early as at 6 months on treatment. Regarding safety, 21 (42%) patients had ≥1 grade 3/4 adverse event (AE); the most common was thrombocytopenia (n = 9, 18%). 14 (28%) patients had ≥1 serious AE (SAE), the most common being acute kidney injury and pneumonia (n = 2, each). Four patients died due to infections. In conclusion, second‐line treatment with Dara‐Ixa‐dex in patients with RRMM pre‐treated with a lenalidomide‐based regimen resulted in rapid responses along with a favorable effect on bone metabolism.

2024-02-01·American Journal of Hematology

Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment

Article

作者: Gertz, Morie A

Abstract:

Disease Overview:

Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and “atypical smoldering multiple myeloma or MGUS.”

Diagnosis:

Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for the diagnosis of AL amyloidosis. Organ biopsy is not required in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. The gold standard is laser capture mass spectroscopy.

Prognosis:

N‐terminal pro–brain natriuretic peptide (NT‐proBNP or BNP), serum troponin T(or I), and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four stages; 5‐year survivals are 82%, 62%, 34%, and 20%, respectively.

Therapy:

All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Current first‐line therapy with the best outcome is daratumumab, bortezomib, cyclophosphamide, and dexamethasone. The goal of therapy is a ≥VGPR. In patients failing to achieve this depth of response options for consolidation include pomalidomide, stem cell transplantation, venetoclax, and bendamustine.

Future Challenges:

Delayed diagnosis remains a major obstacle to initiating effective therapy prior to the development of end‐stage organ failure. Trials of antibodies to deplete deposited fibrils are underway.

Haematologica

Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant

Article

作者: Begna, Kebede H ; Gangat, Naseema ; Mangaonkar, Abhishek A ; Janania-Martinez, Michelle ; Abdallah, Nadine H ; Rangan, Aruna ; Herrick, Jennifer L

Not available.

641

项与达雷妥尤单抗相关的新闻（医药）

2024-04-18

·医药魔方

2023年全球畅销药TOP100

随着各大药企2023年财报陆续披露，全球畅销药品也随之诞生。在此，医药魔方整理了销售额TOP100的药品榜单。2023年，约有152款药物销售额超过10亿美元；TOP100药品的上榜门槛是16.79亿美元（折合人民币约128.32亿元），合计销售总收入为4567.75亿美元。2023年全球药品销售额TOP100（亿美元）注：1）根据2023年平均汇率换算：1欧元=1.0845美元，1英镑=1.2479美元，100日元=0.71452美元，1瑞士法郎=1.1177美元，1元人民币=0.14191美元；2）武田、卫材等日本企业为2023自然年收入。相较去年，2023年畅销药TOP100名单发生巨大变化。首先，新冠类产品大幅退出，这主要是因为疫情解除后疫苗以及治疗药物的需求急速萎缩，对TOP100上榜门槛以及总体数量都有不同程度的影响。其次，诸多老产品收入下滑严重，前“药王”修美乐在专利断崖的冲击下销售额大幅跳水，并由K药接任新“药王”，同时包括来那度胺、依那西普、伊布替尼等在内的多款重磅产品也在专利到期后受到仿制药/生物类似药侵蚀中持续下降。第三，新产品快速崛起，包括司美格鲁肽、替尔泊肽这类GLP-1公众明星产品，以及度普利尤单抗、利生奇珠单抗等新生代专科药物销售收入飙升。此外，2023年的畅销药榜单还有一大亮点，有10款药物实现了100亿+美元销售额，这是历史上 “超级重磅炸弹”药物最多的一个年份（见：100亿+美元超级重磅炸弹药物，为什么越来越多了？）。从TOP100药物的疾病领域分布看，除了感染病类药品数量和销售总额在2023年有大幅减少，其余领域包括肿瘤、免疫、内分泌、心血管等疾病领域都有所增涨。其中，肿瘤、免疫市场规模仍然最大，分别以28%、20%的比重达成了约1296亿美元和920亿美元市场份额。2023年TOP100药品疾病领域分布(数量、销售额)此外，入围TOP100榜单的药物类型总体变化也不大，小分子类药物共计45款，单抗类31款，两大类别实现的销售总额分别为1758.71亿美元、1639.87亿美元。2023年TOP100药品类型分布（数量、销售额）从企业维度来看，TOP100药品的企业分布较以往也无太多变化，只不过各家的数量有着细微变动。其中，强生以11款药品居于首位，与2022年相同，目前有一半产品收入处于下滑状态，但其核心驱动因子乌司奴单抗、古赛奇尤单抗以及达雷妥尤单抗、阿帕他胺销售收入仍保持稳定的增长趋势。2023年药品销售额TOP100企业分布罗氏以11款的数量并列排位第一，较2022年虽然减少了雷珠单抗和利妥昔单抗，不过新产品--眼科双抗法瑞西单抗已经强势填补空缺，2023年销售表现十分出彩。诺华数量以两进两出维持了动态平衡，其中雷珠单抗、芬戈莫德在竞品以及生物类似药/仿制药的冲击下销售额连年下滑，跌落榜单，目前席位已由2款新产品奥法妥木单抗和瑞波西利替补。阿斯利康数量发生变动主要受到2款新冠产品影响，不过其与第一三共合作开发的德曲妥珠单抗正处于快速放量中。总体而言，TOP100榜单的排位顺序变化，一方面反映了过去一年产品的销售表现差异，另一方面也能折射出各家企业整体业绩的浮动，甚至还能体现其核心业务的变迁历程。随着老产品的日渐式微以及新产品的成熟壮大，接下来的一年会有什么样的市场格局变化，十分值得期待。推荐阅读2022年全球药品销售额TOP1002021年全球药品销售额TOP1002020年全球药品销售额TOP1002019年全球药品销售额TOP1002018年全球药品销售额Top100Copyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。精彩预告线下沙龙↑ 长按扫码，报名活动 ↑

财报疫苗专利到期生物类似药

2024-04-18

·Pharma CMC

强生2024 Q1：CAR-T疗法Carvykti大卖11亿元

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。2024年4月16日，强生发布了2024年第一季度业绩：2024 Q1销售额达到213.83亿美元，同比增长2.3%；研发费用35.42亿美元，同比增长2.5%。从具体业务划分来看，2024 Q1创新药业务营收135.62亿美元，同比增长1.1%。医疗设备部门业务营收78.21亿美元美元，同比增长4.5%。从地区来看，美国业务是强生的支柱。2024 Q1营收116.2亿美元，同比增长7.8%，美国以外地区的国际业务全年营收97.63亿美元，同比增长3.4%。强生的创新药业务主要聚焦于自身免疫、肿瘤、神经科学、感染、肺动脉高压、心血管及代谢几大领域。在创新药业务中，拉动增长的主要因素是：免疫治疗产品TREMFYA (古塞奇尤单抗) 、SIMPONI/SIMPONI ARIA （戈利木单抗）、STELARA (乌司奴单抗) ；抗肿瘤产品DARZALEX (达雷妥尤单抗)、ERLEADA (阿帕他胺)、TECVAYLI (特立妥单抗) 、CARVYKTI (西达基奥仑赛)；肺动脉高压治疗药物Opsumit(马西替坦)和UPTRAVI（司来帕格）。在肿瘤领域，强生与传奇生物合作的BCMA CAR-T疗法Carvykti的销售成绩是一大亮点。Carvykti 2024 Q1总销售额为1.57亿美元（约11亿元），较去年同期大增118%，2024年有望突破10亿美元（目前仅美国、欧盟、日本上市）。Carvykti是一种靶向BCMA的CAR-T细胞疗法，使用嵌合抗原受体的转基因对患者自身的T细胞进行修饰，以识别和消除表达BCMA的细胞。2024年4月15日，美国食品和药物管理局(FDA)已批准Carvykti用于治疗复发性或难治性多发性骨髓瘤患者，CARVYKTI®是首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原 (BCMA) 靶向疗法。此外，自免领域已逐渐成为制药巨头业绩的重要支柱，Stelara仍是强生自免版块增长的主要驱动力，2024 Q1总销售额为24.51亿美元，同比增长0.3%。伴随Stelara核心专利到期，随着生物仿制药进入欧洲市场，Stelara的收入预计将开始下降。新一代靶向IL-23 p19的单抗Tremfya顺利接棒，在2024 Q1创下了8.08亿美元的销售额。强生早已未雨绸缪，开始了在肿瘤、感染、心血管等多个领域的布局。目前有13个药物处于NDA阶段，39款药物处于临床3期，20款药物处于临床2期，23款药物处于临床1期。强生还将全年的运营销售增长预期从5.5%提高到6%（887亿美元至891亿美元），而之前的预期为5%至6%（882亿美元至890亿美元）。2024年，强生将在新药/适应症的监管批准、上市申请的提交以及临床数据的读出方面实现多个里程碑。参考资料：公司官网

细胞疗法免疫疗法财报ASH会议

2024-04-17

·药时代

强生，重回巅峰；诺和诺德，涨幅最大；辉瑞，名列第四——全球药企收入排行榜出炉！

正文共2466字共8图预计阅读时间：7分钟01强生再次荣登全球药企收入榜首。近日，Fierce Pharma发布了2023年全球收入前20的药企名单，其中强生以851.6亿美元（制药业务+医疗器械业务）的营收再次登顶榜首，领先第二名罗氏近200亿美元。这还没有算上Kenvue——强生的消费者健康业务。2022年9月，强生正式剥离消费者健康业务，以Kenvue为名独立上市。据悉，2023年Kenvue营收共154亿美元。若加上Kenvue贡献的营收，强生2023年的实际收入已然超出1000亿美元，是第二家年收入突破1000亿美元的药企。第一家年收入突破1000亿美元的药企是辉瑞。2022年，辉瑞跟BioNtech合作的mRNA新冠疫苗销售额为378亿美元，Paxlovid销售额为189亿美元，单凭两款新冠产品辉瑞就拿下了557亿美元。此次强生重新登顶，是大部分业内人士意料之中的事。2022年，连续十年稳坐全球药企收入TOP1宝座的强生首次让位辉瑞，后者凭借几款新冠产品在近几年大方光彩。随着新冠产品收入下滑，辉瑞的收入下滑在预期中，强生再次登顶也是顺其自然。根据强生公告信息，预计在2025~2030年期间将公司收入将保持5%~7%的年增长率，其制药业务收入也将稳步增长，有望在2024年贡献570亿美元的收入。若无意外，明年药企收入TOP1的位置大概率还是强生的。得出这个结论，一方面是考虑到强生与其他药企的收入相比的确优势明显，其他药企很难在一年内跨越这个差距。目前，医药板块是强生的最大收入来源，2023年共营收547.6亿美元。其医疗器械板块2023年营收304亿美元，这是其营收能与其他药企拉开距离的主要原因之一。另一方面则是基于强生如今表现出的稳定增长能力。根据强生近日发布信息，2024 Q1强生共营收213.8亿美元，相比2023 Q1（208.9亿美元）增长约2%。此外，强生旗下还有如Darzalex（达雷妥尤单抗）、Erleada（阿帕他胺）这样增幅还不错的大单品，足以在很长一段时间内为公司业绩提供稳定增长。02接下来讲讲2023年收入增幅最大诺和诺德。根据FiercePharma统计数据，2023年诺和诺德共营收232亿丹麦克朗，约合337亿美元，同比增长31.5%。全年收入在全球药企中排名12，相比去年第17名的成绩，一年内排名上升5名。诺和诺德巨大的成功背后，是GLP-1产品司美格鲁肽的助力。司美格鲁肽，2023年的顶流，业界花名“减肥神药”。目前，诺和诺德的司美格鲁肽产品主要为：注射用降糖产品Ozempic、注射用减重产品Wegovy、口服降糖产品Rybelsus。这三款产品在2023年共为诺和诺德贡献了1458.11亿丹麦克朗（212.01亿美元）的营收，几乎是诺和诺德全年营收的2/3。这里需要提的一点是，GLP-1产品因其出类拔萃的适应症可及性和减肥适应症带来的一部分消费属性，市场容量很大，短期内应该不会出现因同类产品竞争而导致营收下滑的情况。多方面考虑下，诺和诺德的司美格鲁肽产品目前最大的困境是产能不足，也就是说，只要解决了产能问题，诺和诺德的营收还有很大上升空间。而根据过去一年的消息，诺和诺德正在马不停蹄的建厂扩能。同样吃到了GLP-1类产品红利的还有礼来，2023年礼来营收341亿美元，同比增长20%，营收排名第11，增幅仅次于诺和诺德。除了已上市的两款替尔泊肽产品（Mounjaro+Zepbound），目前其还在研的三靶点减肥药Retatrutide已经展现出不小的潜力。凭借多款在研的/已上市的重磅产品，业内对礼来的期待极高，目前已经是市值排名第一的MNC。03接下来聊聊降幅最大药企——辉瑞。2023年，辉瑞共营收585亿美元，相比2022年的辉煌战绩，营收直接腰斩。但这并不影响辉瑞2023年营收仍在一众药企中排到了第4名。辉瑞营收的惊人降幅有一个公开的原因——新冠产品营收锐减。根据辉瑞财报，2023年新冠mRNA疫苗Comirnaty营收缩减70%，新冠治疗药物Paxlovid营收缩减90%。辉瑞官方信息提到，不考虑新冠产品带来的影响，其实公司整体营收仍保持良好的增长状态，同比增长可达7%。营收增长较快的有心脏病新药Vyndaqel 和 Vyndamax（同比增长36%）、RSV疫苗产品Abrysvo（2023年上市）、偏头痛新药Nurtec ODT/Vydura等。公告也提到，之后几年的增长很有可能将来自其430亿美元买下的Seagen。据悉，Seagen的管线中正孕育着不少有望10亿美元分子的重磅产品，有多达25个抗癌药物，有望覆盖超40种适应症，很值得期待。可见在后疫情时代，营收回归正常水平的辉瑞仍有向前一步的可能。除了以上提到的，随着凭借新冠产品大卖崛起的新贵退出，晖致重新回归营收前20药企榜单。另外，其余药企2023年的营收都在可接受范围内小幅度波动，宏观角度来看，均属于一家药企运营的正常状态。下图为2023年全球收入TOP20药企榜单，数据由Fierce Pharma提供。参考资料1.各公司官网2.www.fiercepharma.com3.其他公开资料封面图来源：pixabay版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn强生公布Q1财报：营收214亿美元，Carvykti销售额达1.6亿美元！ODAC全票通过！MRD有望成为多发性骨髓瘤加速批准的试验终点AACR之后，又会有多少BD交易产生？点击阅读原文，了解更多！

财报疫苗信使RNA核酸药物

100 项与达雷妥尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10777	达雷妥尤单抗	L01XC24	DB09331

研发状态

适应症	最高研发状态	国家/地区	公司
多发性骨髓瘤	批准上市	日本更多	Janssen Pharmaceutical KK 更多
免疫球蛋白轻链淀粉样变性	批准上市	挪威更多	Janssen-Cilag International NV 更多
阴燃多发性骨髓瘤	临床3期	-	Janssen Research & Development LLC 更多
浆细胞骨髓瘤难治	临床3期	塞尔维亚更多	Janssen Research & Development LLC 更多
淀粉样变性	临床3期	波兰更多	西安杨森制药有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CASTOR and POLLUX (Pubmed)	临床3期	骨髓瘤复发	-	Daratumumab plus bortezomib/dexamethasone (D-Vd)	獵窪憲觸鬱夢艱淵醖糧(襯襯繭廠齋衊憲糧簾窪) = Rates of ≥CR and MRD negativity (10−5) were higher with daratumumab vs control, regardless of progression/relapse timing 顧顧艱淵衊鏇獵襯鹽糧 (願餘壓憲選鹹淵網艱繭 )	-	2024-01-23
CASTOR and POLLUX (Pubmed)	临床3期	骨髓瘤复发	-	Daratumumab plus lenalidomide/dexamethasone (D-Rd)		-	2024-01-23
NCT03710603 (PERSEUS, ASH2023) 人工标引	临床3期	多发性骨髓瘤	709	Daratumumab+velcade+lenalidomide+dexamethasone	積觸鹹觸窪壓繭遞窪鑰(繭窪淵範選製鬱範醖鹹) = not reached in either arm 夢繭齋鏇範糧鏇鬱淵齋 (壓膚齋鹹鹽鹹鬱獵艱鹽 ) 更多	积极	2023-12-12
NCT03710603 (PERSEUS, ASH2023) 人工标引	临床3期	多发性骨髓瘤	709	Velcade+lenalidomide+dexamethasone		积极	2023-12-12
Columbia Amyloidosis Multidisciplinary Program (ASH2023)	N/A	免疫球蛋白轻链淀粉样变性	-	Daratumumab-based frontline therapy	膚築築顧簾觸艱願窪顧(衊蓋糧襯醖淵鑰構窪蓋) = 鏇觸鏇繭襯繭築窪顧醖窪範膚淵願選鹽遞鏇製 (糧夢築鏇淵觸繭積齋構, 3.4 ~ 15.9) 更多	-	2023-12-11
ASH2023	临床2期	造血干细胞移植	42	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone	壓鑰壓遞襯鬱鹹觸網鏇(獵窪顧膚繭艱築遞獵窪) = 糧齋壓艱憲製廠構蓋獵襯蓋壓餘鑰餘顧築鹹範 (觸鹽膚夢齋蓋鏇顧鬱夢 ) 更多	-	2023-12-11
CASSIOPEIA (ASH2023)	N/A	-	109	Daratumumab-Bortezomib-Thalidomide-Dexamethasone (Dara-VTD)	選衊醖衊遞觸鑰構獵觸(淵製蓋選醖齋獵繭鹽艱) = 繭繭築顧鬱憲顧窪鹹壓鑰築範築餘觸鏇鏇餘壓 (齋壓醖醖蓋襯遞餘鑰窪, 3.9 ~ 5.47)	-	2023-12-11
CASSIOPEIA (ASH2023)	N/A	-	109	Bortezomib-Thalidomide-Dexamethasone (VTD)Bortezomib-Thalidomide-Dexamethasone (VTD)Bortezomib-Thalidomide-Dexamethasone (VTD)	選衊醖衊遞觸鑰構獵觸(淵製蓋選醖齋獵繭鹽艱) = 鑰鬱選衊糧淵繭衊鬱衊鑰築範築餘觸鏇鏇餘壓 (齋壓醖醖蓋襯遞餘鑰窪, 6.35 ~ 11.15)	-	2023-12-11
NCT03763162 (ASH2023)	临床2期	浆细胞骨髓瘤难治	40	Daratumumab, Bortezomib, DexamethasoneDaratumumab, Bortezomib, DexamethasoneDaratumumab, Bortezomib, Dexamethasone	選醖簾製構鹽構選齋網(醖製簾窪積鹽願醖築廠) = 遞鹹淵夢鏇淵襯築顧築餘鹹膚齋衊窪願艱蓋顧 (鏇鏇願鬱壓艱鑰築鹽廠 ) 更多	-	2023-12-11
ALCYONE (ASH2023)	N/A	多发性骨髓瘤一线	111	Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP)	構鑰齋構鏇觸醖範鑰積(願繭艱網廠壓齋鏇艱網) = 簾選壓蓋憲壓遞選衊積糧範憲繭製顧鏇範觸衊 (簾膚獵願繭構醖餘鬱憲 ) 更多	-	2023-12-11
ASH2023	临床2期	免疫球蛋白轻链淀粉样变性	47	Low-frequency Daratumumab	艱餘範遞壓憲膚鏇繭積(憲鑰範築壓鬱網醖鹽鑰) = 7 patients, 18.4% 鏇糧選襯蓋餘鑰鑰顧構 (憲範積遞鑰膚顧鏇鑰衊 ) 更多	-	2023-12-10
NCT04131309 (EMN22, ASH2023)	临床2期	免疫球蛋白轻链淀粉样变性	40	Daratumumab monotherapy	夢簾網艱鑰襯網鏇膚鹹(範簾壓廠簾蓋觸顧繭醖) = 膚鬱簾範構窪鏇築選獵膚醖積窪鏇獵襯淵窪鹹 (蓋餘襯積積積夢願鹽選 ) 更多	-	2023-12-10
ASH2023	N/A	多发性骨髓瘤	-	Daratumumab, Lenalidomide, and Dexamethasone (DRd)	鹹鏇夢獵餘鏇蓋糧鏇壓(衊憲憲餘憲觸築願淵襯) = 繭構獵糧齋製積範壓鏇觸顧遞廠鬱鬱鑰膚遞憲 (獵壓繭顧簾構鬱蓋餘鑰 )	-	2023-12-10
ASH2023	N/A	多发性骨髓瘤	-	Bortezomib, Lenalidomide, and Dexamethasone (VRd)	鹹鏇夢獵餘鏇蓋糧鏇壓(衊憲憲餘憲觸築願淵襯) = 廠觸簾淵艱憲衊鹽廠夢觸顧遞廠鬱鬱鑰膚遞憲 (獵壓繭顧簾構鬱蓋餘鑰 )	-	2023-12-10